Baxter International Inc (NYSE:BAX) is Sector Gamma AS’s 4th Largest Position

Sector Gamma AS increased its stake in Baxter International Inc (NYSE:BAX) by 2.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 472,305 shares of the medical instruments supplier’s stock after acquiring an additional 10,000 shares during the period. Baxter International comprises approximately 7.0% of Sector Gamma AS’s portfolio, making the stock its 4th largest position. Sector Gamma AS owned about 0.09% of Baxter International worth $41,313,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in BAX. 1 North Wealth Services LLC purchased a new stake in Baxter International during the third quarter valued at about $27,000. Personal Wealth Partners purchased a new stake in Baxter International during the second quarter valued at about $29,000. TRUE Private Wealth Advisors purchased a new stake in Baxter International during the second quarter valued at about $29,000. Old North State Trust LLC purchased a new stake in Baxter International during the third quarter valued at about $31,000. Finally, Evolution Wealth Advisors LLC purchased a new stake in Baxter International during the second quarter valued at about $32,000. Institutional investors own 83.45% of the company’s stock.

In related news, SVP Andrew Frye sold 3,332 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $88.00, for a total value of $293,216.00. Following the completion of the transaction, the senior vice president now directly owns 16,391 shares of the company’s stock, valued at $1,442,408. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jacqueline Kunzler sold 5,934 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $88.12, for a total transaction of $522,904.08. Following the completion of the transaction, the senior vice president now directly owns 3,089 shares of the company’s stock, valued at $272,202.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,396 shares of company stock valued at $1,528,575. 0.70% of the stock is owned by insiders.

BAX has been the subject of several analyst reports. Deutsche Bank started coverage on shares of Baxter International in a research report on Monday, October 21st. They set a “buy” rating and a $109.00 price target for the company. JPMorgan Chase & Co. set a $94.00 target price on shares of Baxter International and gave the stock a “buy” rating in a report on Tuesday, October 8th. BMO Capital Markets increased their target price on shares of Baxter International to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Raymond James increased their target price on shares of Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Finally, Credit Suisse Group increased their target price on shares of Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Baxter International presently has an average rating of “Buy” and a consensus target price of $90.14.

BAX stock traded up $0.51 during trading on Friday, reaching $78.51. The company had a trading volume of 3,017,392 shares, compared to its average volume of 2,768,937. Baxter International Inc has a 52 week low of $61.40 and a 52 week high of $89.93. The company has a market cap of $39.56 billion, a P/E ratio of 25.74, a PEG ratio of 2.00 and a beta of 0.97. The business has a 50 day moving average of $84.08 and a 200 day moving average of $82.11. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: How Do Front-End Loads Impact an Investment?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.